AstraZeneca boosts capacity for coronavirus vaccine candidate, receives US$1bn in US funding
Expenses for the vaccine, which will not be produced for a profit during the pandemic, are expected to be offset by funding by governments
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 30 of 55
Coronavirus: Moderna Inc announces positive interim results on vaccine candidate
The latest developments on projects to tackle the pandemic
AstraZeneca’s Enhertu fast-tracked for lung cancer treatment
The pharma giant also announced Bevespi Aerosphere was approved in China for patients with chronic obstructive pulmonary disease
AstraZeneca receives US approval for a combination with Lynparza in advanced ovarian cancer
The firm also announced it completed the recovery of global rights to brazikumab while its candidate Enhertu received a fast-track designation
AstraZeneca says Farxiga heart drug receives US green light
Farxiga has been shown to reduce the risk of death and hospitalisation for cardiovascular patients with a condition called reduced ejection fraction
AstraZeneca agrees to produce Oxford University’s coronavirus vaccine candidate on not-for-profit basis
The pharma giant would be responsible for the development and worldwide manufacturing and distribution of the candidate, if and when it is approved
AstraZeneca maintains guidance after strong start to year, buoyed by fast-growing oncology portfolio
It is also said it is committed to a progressive dividend policy
AstraZeneca PLC may be the UK's largest company, but it and other pharma giants rely in small-cap biotech for new medicines, according Arix pair
Arix is a backer of innovative smaller life sciences companies developing potentially breakthrough new medicines
AstraZeneca cancer drug passes prostate trial milestone
Lynparza successfully achieved a second goal when deployed to treat men with an advanced form of the disease
AstraZeneca to trial blood cancer drug for coronavirus treatment
“This is the fastest launch of any clinical trial in the history of AstraZeneca," according to José Baselga, the group's executive vice president in the oncology research and development segment
AstraZeneca’s target price upped to 8,870p by Liberum over oncology pipeline potential
The broker, which retains a 'buy' recommendation, said the pharma giant is expected to be “a long-term outperformer”
AstraZeneca stops chronic kidney disease treatment trial early after “overwhelming efficacy”
The pharma company also announced Imfinzi has been approved for small cell lung cancer in combination with chemotherapies
Archive
Small cap movers: Genedrive skyrockets with coronavirus test production ramp-up
A look back at some of the more interesting stories from London's junior market this week
AstraZeneca posts negative results for late-stage bladder cancer treatment
The base drug for the treatment is being tested in conjunction with chemotherapy in patients with the same disease
AstraZeneca completes sale of hypertension drugs rights
The initial US$350mln payment may be followed by optional instalments of up to US$40mln based on sales
AstraZeneca sells rights for constipation drug to RedHill Biopharma
AstraZeneca will retain rights to sell Movantik in Europe, Canada and Israel
AstraZeneca revenues surge ahead but coronavirus clouds current year
Sales will be driven by cancer drugs Enhertu, Lynparza and selumetinib in various markets and anaemia treatment Roxadustat in China
Archive
FTSE 100 closes lower as coronavirus fears and corporate updates hit equities
Britain's blue-chip index closed down nearly 43 points at 7,409. The FTSE 250, conversely, went higher, gaining over 116 points at 21,790
AstraZeneca and Royal Bank of Scotland on the cards for Valentine’s Day
The two FTSE 100 constituents are scheduled to release their final results
Can AstraZeneca, Barclays and RBS's numbers provide a shot in the arm?
Other updates on the coming week's agenda include Ocado, TUI, Babcock and Dunelm